With no prior business experience, he started his journey with just two employees and transformed his company into a global ...

Sun Pharmaceuticals, India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Sun Pharmaceutical Industries Ltd. 524715 shares slid 1.14% to 1,779.30 Indian rupees Wednesday, on what proved to be an all-around poor trading session for the stock market, with the BSE SENSEX Index ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

This segment, which Sun Pharma calls 'high growth', contributed to more than 18% of its total sales in fiscal year 2024. Sun Pharma, which also makes copycat generic drugs and branded versions ...

India's Sun Pharmaceutical has signed an agreement ... that will be paid to Concert shareholders if deuroxilitinib meets certain sales targets within a set time limit. Alopecia areata is an ...

Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

The consolidated R&D (research and development) investments for the quarter were at Rs 793 crore, representing 6 per cent of sales, compared to Rs 773.4 crore in Q2FY24. Sun Pharma has a comprehensive ...

Chennai: Pharma market reported better revenue growth in Q2 FY25 against the year-ago quarter, mainly driven by price rise ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...